CLINICAL TRIALS- A MODERN APPROACH TECHNOLOGY LEVERAGED TO REDUCE TURNAROUND TIME

by Akanksha Sri Passionate in Blogging

The prospective biomedical research designed to answer several inquiries about clinical research is called a clinical trial. Varied in size and cost, involving single or multiple research centers, it aims to validate scientific progressions in medical infrastructure. In recent times, clinical trials have proved as a way to prevent a health problem by finding disease early, sometimes even before any symptoms arise. The four-phase test determines the appropriate dosage in case of a drug if it is approved for general use or not. This development in medical science has braced up to reduce the turnaround of anatomic pathology solutions.

Though the road to success for these trials hasn't come the easy way that technology had to undergo several criticisms and complications. It was always a debatable issue as to how the most appropriate sample of tissue to test should be critically selected and sampled. The selected specimens are unique and hence, even a minute loss can fail the trial because even though the blood samples and urine samples can be recollected but the biopsies can't. Even though these limitations cannot be sugar-coated when it comes to actual regulation, the effectiveness of this technology left the medical world in awe with the most surprising results. Where earlier, a sample of tissues to be sent for minimal research would consume almost a week or so, these trials would help undergo a deep-rooted multi and atomic research in 2 days with almost half the cost.

The technology used around the globe offers an adaptation to improve methods focused on reduced shipping delays and cost. The increase in enrollment time of a potential study subject results in an increase in the cost of the trial because of which, they now focus on a hassle-free environment to be provided to the patient to avoid disappointment to them due to the loss of interest and delayed procedure.

TURNAROUND TIME - HOW IT EMERGES AS THE MOST IMPORTANT FACTOR IN PERFORMANCE INDICATORS?

Turnaround time is one of the crucial indications of a laboratory's services and the most important indicator of its performance. Traditionally, in medical laboratories, the discussions pertaining to the time affectivity were restricted as the major focus always lied on the efficiency of the trial but as the decades changed and the cost of manpower and machinery became a determining factor in such researches, it resulted in a change of reasoning of the clinicians who now decide a rapid and reliable service at the lowest cost.

The newest emerging technologies of sample collection, multi-tissue tests, patient optimal methodologies, and multiple imputations have helped to reduce the total turnaround time in the process of research. The technological implementation in the procedure to reduce the turnaround has mostly been seen in the time of covid-19 pandemic over the past one point five years. Thousands of clinical trials monitoring have taken place to test life-saving treatments and vaccines for the deadly virus.

DIGITIZING THE TRIALS- AN EFFICACIOUS APPROACH

Digitizing the clinical trials has become a fundamental tool to evaluate the efficacy of new drugs in the least time so that its implementation can be adapted the fastest. Many technical practitioners have laid down the concept of digital clinical trials to improve participant rate, trial process allocation, and potential research to lower the cost. These technologies might include mobile health devices, wearable technologies, or application-based interfaces to regulate the security and privacy of information along with no harm to the research in progress. Machine algorithms and data science approaches have been considered as the primary priorities for the future in such a way that the interface is strategically designed to address the benefits of the clinical trial.

The mechanism of action of clinical trials starts from digital recruitment and retention. This way many trials with the patient study can be done without in-person visits. This, however, has been dappled the most in recent times of covid-19 pandemic where the in-person studies stood as a problem in the plan of action. This was when the technology came to recognition to harness the opportunity to accelerate the pace at which the task is done.

The review-based technology in the clinical trials seems to help reduce the time of the part where the articulation of discrepancies in the trial is done. By this implementation, consolidated reports of combined sample handles can be reviewed in bulk that will eventually result in saving a lot of time and effort. The results of further trials can be seamlessly combined, developing the end prints and analyzing the real data. These developments are more responsive and dooming than the human outcomes of the aforesaid assessments. The evidence and results are reliable and can particularly provide reasonable details of a vast range of signals that can otherwise be not captured.

The new technology has the potential to generate new ideas for processes that can open a whole new world for researchers to dig into the revenue of medical research. The advanced concept of personalized trial and error research can also be responsibly implemented in a much easier way that can give rise to a powerful and innovative product real soon.